Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Pilulka Lekarny AS's Revenue for the
six
months ended in Dec. 2025 was Kč0 Mil. Pilulka Lekarny AS's average Accounts Receivable for the
six
months ended in Dec. 2025 was Kč53 Mil.
Pilulka Lekarny AS (XPRA:PINK) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Pilulka Lekarny AS Receivables Turnover Related Terms
Pilulka Lekarny AS Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Pilulka Lekarny AS's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pilulka Lekarny AS Receivables Turnover Competitor Comparison
For the Pharmaceutical Retailers subindustry, Pilulka Lekarny AS's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pilulka Lekarny AS Receivables Turnover vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pilulka Lekarny AS's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Pilulka Lekarny AS's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pilulka Lekarny AS (XPRA:PINK) has a Receivables Turnover of 0.00 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Pilulka Lekarny AS and its competitors. According to the industry distribution chart, Pilulka Lekarny AS ranks #85 out of 659 companies in the Healthcare Providers & Services industry, placing it in the top 12.9%.
Is Pilulka Lekarny AS's Receivables Turnover too high?
Pilulka Lekarny AS's current Receivables Turnover is 0.00. Based on the distribution chart, Pilulka Lekarny AS ranks #85 out of 659 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Pilulka Lekarny AS has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pilulka Lekarny AS's Receivables Turnover compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Pilulka Lekarny AS ranks #85 out of 659 companies for Receivables Turnover. This places Pilulka Lekarny AS in the top 13% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 7.96. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Healthcare Providers & Services company?
The median Receivables Turnover among Healthcare Providers & Services companies is 7.96, based on 659 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Pilulka Lekarny AS and its competitors. For the Healthcare Providers & Services industry, the median Receivables Turnover is 7.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pilulka Lekarny AS's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pilulka Lekarny AS stock overvalued right now?
Based on GuruFocus' analysis, Pilulka Lekarny AS (XPRA:PINK) is currently considered Fairly Valued. The stock's GF Value™ is Kč111.00, compared to a current price of Kč121.00 — trading 9% above its estimated fair value. The current Receivables Turnover is 0.00. Pilulka Lekarny AS's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Pilulka Lekarny AS (XPRA:PINK), the current Receivables Turnover is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pilulka Lekarny AS (XPRA:PINK) Overvalued in 2026?
Based on GuruFocus' analysis, Pilulka Lekarny AS stock appears to be overvalued.
The current stock price of Kč121.00 is trading 9% above its estimated GF Value™ of Kč111.00.
GuruFocus considers Pilulka Lekarny AS to be Fairly Valued.
Key valuation signals for XPRA:PINK:
Receivables Turnover: 0.00
GF Value™: Kč111.00 vs. price of Kč121.00 (9% above fair value)
No single metric tells the full story. See the XPRA:PINK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pilulka Lekarny AS operates an online pharmaceutical store by distribution of medicinal products. The store offers over-the-counter-drugs, dietary supplements, baby foods, mother care products, cosmetics, other prescription drugs, sport nutritional products, diagnostic test kits, orthopaedic supplies, first aid kits, and other related products.
49GF Score
Get the complete analysis for XPRA:PINK
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPRA:PINK has been successfully added to your 
